AtriCure Reports Strong Q1 2026 Earnings with 14% Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 39 minutes ago
0mins
Should l Buy ATRC?
Source: seekingalpha
- Significant Revenue Growth: AtriCure reported worldwide revenue of $141.2 million in Q1 2026, reflecting a 14.3% year-over-year increase, indicating strong performance in the medical device market, with full-year revenue expectations of $600 to $610 million suggesting a growth potential of 12% to 14%.
- Clinical Trial Progress: The BoxX-NoAF clinical trial has enrolled approximately 300 patients, with completion expected by year-end, nearly a year ahead of schedule, demonstrating the company's proactive approach in innovation and R&D, which will facilitate future product market entry.
- Strong Pain Management Performance: Pain management product sales increased by 28% year-over-year, with the cryoSPHERE MAX probe contributing roughly 70% of sales, underscoring its dominant position in the market and further solidifying AtriCure's competitive edge in this sector.
- Improved Profitability: The gross margin for Q1 2026 reached 77.4%, with adjusted EBITDA of $17.1 million and net income of approximately $100,000, indicating positive progress in cost control and profitability, thereby enhancing investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRC
Wall Street analysts forecast ATRC stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 28.780
Low
45.00
Averages
52.20
High
64.00
Current: 28.780
Low
45.00
Averages
52.20
High
64.00
About ATRC
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AtriCure Reports Strong Q1 2026 Financial Results with 14.3% Revenue Growth
- Significant Revenue Growth: AtriCure's Q1 2026 worldwide revenue reached $141.2 million, marking a 14.3% year-over-year increase, with U.S. revenue at $116.2 million, up 14.9%, indicating strong demand and market share expansion in the atrial fibrillation treatment sector.
- Improved Profitability: The company reported a net income of $108,000 for Q1, with adjusted EBITDA soaring to $17.1 million, a 95% increase, demonstrating significant progress in cost control and operational efficiency, thereby boosting investor confidence.
- Product-Driven Growth: Sales of innovative products like AtriClip FLEX-Mini®, cryoSPHERE®MAX™, and EnCompass®clamp fueled revenue growth in the U.S. market, reflecting the company's successful strategies in product development and market penetration.
- Optimistic Future Outlook: Management projects full-year 2026 revenue to be between $600 million and $610 million, with adjusted EBITDA expected to be around $80 million to $82 million, showcasing confidence in future growth and ongoing positive cash flow generation.
See More
AtriCure Reports Strong Q1 2026 Earnings with 14% Revenue Growth
- Significant Revenue Growth: AtriCure reported worldwide revenue of $141.2 million in Q1 2026, reflecting a 14.3% year-over-year increase, indicating strong performance in the medical device market, with full-year revenue expectations of $600 to $610 million suggesting a growth potential of 12% to 14%.
- Clinical Trial Progress: The BoxX-NoAF clinical trial has enrolled approximately 300 patients, with completion expected by year-end, nearly a year ahead of schedule, demonstrating the company's proactive approach in innovation and R&D, which will facilitate future product market entry.
- Strong Pain Management Performance: Pain management product sales increased by 28% year-over-year, with the cryoSPHERE MAX probe contributing roughly 70% of sales, underscoring its dominant position in the market and further solidifying AtriCure's competitive edge in this sector.
- Improved Profitability: The gross margin for Q1 2026 reached 77.4%, with adjusted EBITDA of $17.1 million and net income of approximately $100,000, indicating positive progress in cost control and profitability, thereby enhancing investor confidence.
See More
AtriCure Q1 Earnings Exceed Expectations
- Earnings Highlights: AtriCure reported a Q1 non-GAAP EPS of $0.00, beating expectations by $0.06, indicating an improvement in profitability despite not achieving positive earnings.
- Revenue Growth: The company generated $141.2 million in revenue for Q1, reflecting a 14.2% year-over-year increase and surpassing market expectations by $1.43 million, showcasing strong market demand and sales performance.
- 2026 Financial Guidance: Management projects full-year 2026 revenue to be between $600 million and $610 million, with adjusted EBITDA expected to range from $80 million to $82 million, reflecting confidence in future growth.
- Cash Flow Outlook: The management also anticipates continued positive cash flow generation for 2026, indicating ongoing improvements in financial health and operational efficiency, which bolsters investor confidence.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
AtriCure Chief Scientific Officer Sells 5,000 Shares Amid Negative Returns
- Insider Transaction Overview: On March 12, 2026, AtriCure's Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares valued at $149,150, reducing his direct holdings to 96,875 shares with a post-transaction value of $2.86 million, reflecting a concerning backdrop of a -9.67% total return over the past year.
- Transaction Scale Analysis: This sale marks Vinayak's largest transaction in the past year, surpassing his previous two sales of 2,500 shares each in May and August 2025, indicating a more aggressive approach to reducing his stake, although he still maintains a significant overall position.
- Market Environment Impact: At the time of the transaction, AtriCure's shares were priced at $29.83, closing at $29.54 on the transaction date, highlighting the company's underperformance in the market, and Vinayak's sale occurring during a downturn may reflect uncertainties about future market conditions.
- Investor Considerations: Shortly before this sale, Vinayak received approximately 45,000 shares in restricted stock and performance awards, transferring about 15,600 shares for tax withholding; while this transaction accounted for 4.91% of his direct holdings, his overall stake remains substantial, prompting investors to consider his continued commitment to the company he helps lead.
See More
AtriCure Reports Strong Q1 2026 Financial Results with 14.3% Revenue Growth
- Significant Revenue Growth: AtriCure's Q1 2026 worldwide revenue reached $141.2 million, marking a 14.3% year-over-year increase, with U.S. revenue at $116.2 million, up 14.9%, indicating strong demand and market share expansion in the atrial fibrillation treatment sector.
- Improved Profitability: The company reported a net income of $108,000 for Q1, with adjusted EBITDA soaring to $17.1 million, a 95% increase, demonstrating significant progress in cost control and operational efficiency, thereby boosting investor confidence.
- Product-Driven Growth: Sales of innovative products like AtriClip FLEX-Mini®, cryoSPHERE®MAX™, and EnCompass®clamp fueled revenue growth in the U.S. market, reflecting the company's successful strategies in product development and market penetration.
- Optimistic Future Outlook: Management projects full-year 2026 revenue to be between $600 million and $610 million, with adjusted EBITDA expected to be around $80 million to $82 million, showcasing confidence in future growth and ongoing positive cash flow generation.
See More
AtriCure Reports Strong Q1 2026 Earnings with 14% Revenue Growth
- Significant Revenue Growth: AtriCure reported worldwide revenue of $141.2 million in Q1 2026, reflecting a 14.3% year-over-year increase, indicating strong performance in the medical device market, with full-year revenue expectations of $600 to $610 million suggesting a growth potential of 12% to 14%.
- Clinical Trial Progress: The BoxX-NoAF clinical trial has enrolled approximately 300 patients, with completion expected by year-end, nearly a year ahead of schedule, demonstrating the company's proactive approach in innovation and R&D, which will facilitate future product market entry.
- Strong Pain Management Performance: Pain management product sales increased by 28% year-over-year, with the cryoSPHERE MAX probe contributing roughly 70% of sales, underscoring its dominant position in the market and further solidifying AtriCure's competitive edge in this sector.
- Improved Profitability: The gross margin for Q1 2026 reached 77.4%, with adjusted EBITDA of $17.1 million and net income of approximately $100,000, indicating positive progress in cost control and profitability, thereby enhancing investor confidence.
See More
AtriCure Q1 Earnings Exceed Expectations
- Earnings Highlights: AtriCure reported a Q1 non-GAAP EPS of $0.00, beating expectations by $0.06, indicating an improvement in profitability despite not achieving positive earnings.
- Revenue Growth: The company generated $141.2 million in revenue for Q1, reflecting a 14.2% year-over-year increase and surpassing market expectations by $1.43 million, showcasing strong market demand and sales performance.
- 2026 Financial Guidance: Management projects full-year 2026 revenue to be between $600 million and $610 million, with adjusted EBITDA expected to range from $80 million to $82 million, reflecting confidence in future growth.
- Cash Flow Outlook: The management also anticipates continued positive cash flow generation for 2026, indicating ongoing improvements in financial health and operational efficiency, which bolsters investor confidence.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
AtriCure Chief Scientific Officer Sells 5,000 Shares Amid Negative Returns
- Insider Transaction Overview: On March 12, 2026, AtriCure's Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares valued at $149,150, reducing his direct holdings to 96,875 shares with a post-transaction value of $2.86 million, reflecting a concerning backdrop of a -9.67% total return over the past year.
- Transaction Scale Analysis: This sale marks Vinayak's largest transaction in the past year, surpassing his previous two sales of 2,500 shares each in May and August 2025, indicating a more aggressive approach to reducing his stake, although he still maintains a significant overall position.
- Market Environment Impact: At the time of the transaction, AtriCure's shares were priced at $29.83, closing at $29.54 on the transaction date, highlighting the company's underperformance in the market, and Vinayak's sale occurring during a downturn may reflect uncertainties about future market conditions.
- Investor Considerations: Shortly before this sale, Vinayak received approximately 45,000 shares in restricted stock and performance awards, transferring about 15,600 shares for tax withholding; while this transaction accounted for 4.91% of his direct holdings, his overall stake remains substantial, prompting investors to consider his continued commitment to the company he helps lead.
See More
